Music therapy for people with substance use disorders
文献类型：期刊论文
| 作者 | Ghetti, Claire6; Chen, Xi-Jing5 ; Brenner, Annette K.4; Hakvoort, Laurien G.3; Lien, Lars2; Fachner, Jorg1; Gold, Christian4
|
| 刊名 | COCHRANE DATABASE OF SYSTEMATIC REVIEWS
 |
| 出版日期 | 2022 |
| 期号 | 5页码:103 |
| ISSN号 | 1469-493X |
| DOI | 10.1002/14651858.CD012576.pub3 |
| 通讯作者 | Ghetti, Claire(claire.ghetti@uib.no) |
| 英文摘要 | Background Substance use disorder (SUD) is the continued use of one or more psychoactive substances, including alcohol, despite negative effects on health, functioning, and social relations. Problematic drug use has increased by 10% globally since 2013, and harmful use of alcohol is associated with 5.3% of all deaths. Direct effects of music therapy (MT) on problematic substance use are not known, but it may be helpful in alleviating associated psychological symptoms and decreasing substance craving. Objectives To compare the effect of music therapy (MT) in addition to standard care versus standard care alone, or to standard care plus an active control intervention, on psychological symptoms, substance craving, motivation for treatment, and motivation to stay clean/sober. Search methods We searched the following databases (from inception to 1 February 2021): the Cochrane Drugs and Alcohol Specialised Register; CENTRAL; MEDLINE (PubMed); eight other databases, and two trials registries. We handsearched reference lists of all retrieved studies and relevant systematic reviews. Selection criteria We included randomised controlled trials comparing MT plus standard care to standard care alone, or MT plus standard care to active intervention plus standard care for people with SUD. Data collection and analysis We used standard Cochrane methodology. Main results We included 21 trials involving 1984 people. We found moderate-certainty evidence of a medium effect favouring MT plus standard care over standard care alone for substance craving (standardised mean difference (SMD) -0.66, 95% confidence interval (CI) -1.23 to -0.10; 3 studies, 254 participants), with significant subgroup differences indicating greater reduction in craving for MT intervention lasting one to three months; and small-to-medium effect favouring MT for motivation for treatment/change (SMD 0.41, 95% CI 0.21 to 0.61; 5 studies, 408 participants). We found no clear evidence of a beneficial effect on depression (SMD -0.33, 95% CI -0.72 to 0.07; 3 studies, 100 participants), or motivation to stay sober/clean (SMD 0.22, 95% CI -0.02 to 0.47; 3 studies, 269 participants), though effect sizes ranged from large favourable effect to no effect, and we are uncertain about the result. There was no evidence of beneficial effect on anxiety (mean difference (MD) -0.17, 95% CI -4.39 to 4.05; 1 study, 60 participants), though we are uncertain about the result. There was no meaningful effect for retention in treatment for participants receiving MT plus standard care as compared to standard care alone (risk ratio (RR) 0.99, 95% 0.93 to 1.05; 6 studies, 199 participants). There was a moderate effect on motivation for treatment/change when comparing MT plus standard care to another active intervention plus standard care (SMD 0.46, 95% CI -0.00 to 0.93; 5 studies, 411 participants), and certainty in the result was moderate. We found no clear evidence of an effect of MT on motivation to stay sober/clean when compared to active intervention, though effect sizes ranged from large favourable effect to no effect, and we are uncertain about the result (MD 0.34, 95% CI -0.11 to 0.78; 3 studies, 258 participants). There was no clear evidence of effect on substance craving (SMD -0.04, 95% CI -0.56 to 0.48; 3 studies, 232 participants), depression (MD -1.49, 95% CI -4.98 to 2.00; 1 study, 110 participants), or substance use (RR 1.05, 95% CI 0.85 to 1.29; 1 study, 140 participants) at one-month follow-up when comparing MT plus standard care to active intervention plus standard care. There were no data on adverse effects. Unclear risk of selection bias applied to most studies due to incomplete description of processes of randomisation and allocation concealment. All studies were at unclear risk of detection bias due to lack of blinding of outcome assessors for subjective outcomes (mostly self-report). We judged that bias arising from such lack of blinding would not differ between groups. Similarly, it is not possible to blind participants and providers to MT. We consider knowledge of receiving this type of therapy as part of the therapeutic effect itself, and thus all studies were at low risk of performance bias for subjective outcomes. We downgraded all outcomes one level for imprecision due to optimal information size not being met, and two levels for outcomes with very low sample size. Authors' conclusions Results from this review suggest that MT as 'add on' treatment to standard care can lead to moderate reductions in substance craving and can increase motivation for treatment/change for people with SUDs receiving treatment in detoxification and short-term rehabilitation settings. Greater reduction in craving is associated with MT lasting longer than a single session. We have moderate-to-low confidence in our findings as the included studies were downgraded in certainty due to imprecision, and most included studies were conducted by the same researcher in the same detoxification unit, which considerably impacts the transferability of findings. |
| 收录类别 | SCI |
| WOS关键词 | COGNITIVE-BEHAVIORAL THERAPY ; ASSISTED SYSTEMATIC-DESENSITIZATION ; DETOXIFICATION UNIT ; LYRIC ANALYSIS ; EMOTION REGULATION ; TREATMENT MOTIVATION ; TREATMENT EAGERNESS ; INITIAL VALIDATION ; WORKING ALLIANCE ; CHANGE READINESS |
| 资助项目 | Grieg Academy, University of Bergen, Norway ; NORCE Norwegian Research Centre AS, Bergen, Norway ; POLYFON Kunnskapsklynge for musikkterapi, Norway |
| WOS研究方向 | General & Internal Medicine |
| 语种 | 英语 |
| WOS记录号 | WOS:000804126100013 |
| 出版者 | WILEY |
| 资助机构 | Grieg Academy, University of Bergen, Norway ; NORCE Norwegian Research Centre AS, Bergen, Norway ; POLYFON Kunnskapsklynge for musikkterapi, Norway |
| 源URL | [http://ir.psych.ac.cn/handle/311026/42909]  |
| 专题 | 心理研究所_中国科学院心理健康重点实验室 |
| 通讯作者 | Ghetti, Claire |
| 作者单位 | 1.Anglia Ruskin Univ, Cambridge Inst Mus Therapy Res, Cambridge, England 2.Hosp Innlandet Trust, Norwegian Natl Advisory Unit Concurrent Subst Abu, Brumunddal, Norway 3.ArtEZ Univ Arts, Mus Therapy, Enschede, Netherlands 4.NORCE Norwegian Res Ctr, GAMUT Grieg Acad Mus Therapy Res Ctr AS, Bergen, Norway 5.Chinese Acad Sci, Inst Psychol, CAS Key Lab Mental Hlth, Beijing, Peoples R China 6.Univ Bergen, Grieg Acad, GAMUT Grieg Acad Mus Therapy Res Ctr, Bergen, Norway |
| 推荐引用方式 GB/T 7714 | Ghetti, Claire,Chen, Xi-Jing,Brenner, Annette K.,et al. Music therapy for people with substance use disorders[J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS,2022(5):103. |
| APA | Ghetti, Claire.,Chen, Xi-Jing.,Brenner, Annette K..,Hakvoort, Laurien G..,Lien, Lars.,...&Gold, Christian.(2022).Music therapy for people with substance use disorders.COCHRANE DATABASE OF SYSTEMATIC REVIEWS(5),103. |
| MLA | Ghetti, Claire,et al."Music therapy for people with substance use disorders".COCHRANE DATABASE OF SYSTEMATIC REVIEWS .5(2022):103. |
入库方式： OAI收割
来源：心理研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。